Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intra-lesional Enalaprilat for Hypertrophic Scars
NCT05259137Phase 3Withdrawn
- Sponsor
- Nova Scotia Health
- Start
- Aug 2024
- Primary completion
- Aug 2026
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of enalaprilat in Hypertrophic Scar (HS) (2 arms), sponsored by Nova Scotia Health. Primary endpoint: Patient and Observer Scar Assessment Scale at 52 weeks. Planned start Aug 2024; status: withdrawn.
02
Drugs
enalaprilat
03
Conditions
Hypertrophic Scar (HS)
Beyond the preview
Go deeper on NCT05259137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05259137.